The strengths of the study include the real-life analysis of a cohort of patients with resistant or relapsed MM after treatment failure with anti-CD38 MoABs using a comprehensive dataset from a single center, which is representative of the highly variable MM population that is treated at a tertiary institution. This evidence concerns the gene CD38 and Miyoshi myopathy.